Related Experiment Video
Updated: Dec 23, 2025
09:32
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
7.5K
New and Emerging Biologics for Atopic Dermatitis
Wenelia Baghoomian1, ChanHo Na2, Eric L Simpson3
1School of Medicine, Oregon Health and Science University, Portland, OR, USA.
American Journal of Clinical Dermatology
|April 24, 2020
Summary
Atopic dermatitis (AD) treatments are advancing beyond topical therapies. New biologic drugs targeting specific immune pathways show promise for moderate-to-severe AD patients, offering better efficacy and tolerability.
Area of Science:
- Immunodermatology
- Molecular biology
- Clinical immunology
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition with impaired skin barrier and immune dysregulation.
- Current topical treatments offer limited efficacy and tolerability for moderate-to-severe AD.
- Understanding AD's complex immunopathology is crucial for developing targeted therapies.
Purpose of the Study:
- To review the scientific rationale for novel biologic therapies in AD.
- To summarize ongoing clinical studies of these emerging treatments.
Main Methods:
- Literature review of recent advancements in AD immunopathology.
- Analysis of clinical trial data for novel biologic agents targeting specific cytokines and receptors.
- Exploration of the therapeutic landscape beyond traditional topical treatments.
Main Results:
- The development of targeted biologics, exemplified by dupilumab, is revolutionizing AD treatment.
- Several novel biologic agents targeting key inflammatory pathways are in Phase II and III development.
- These agents aim to improve treatment efficacy and patient quality of life.
Conclusions:
- Novel biologic therapies represent a significant advancement in managing moderate-to-severe atopic dermatitis.
- Targeting specific immune pathways offers a promising therapeutic strategy for AD.
- Further clinical studies are essential to confirm the long-term efficacy and safety of these agents.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
175
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
175
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.6K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.6K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
382
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
382
01:29Inflammatory Bowel Disease IV: Pharmacological Management
379
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
379
01:19Antiasthma Drugs: Leukotriene Modifiers
1.6K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.6K
01:19Clinical Applications of Epidermal Stem Cells
3.1K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.1K